Health Care – Page 2 – The Media Pub News ™

ENHERTU® demonstrated statistically significant and clinically meaningful improvement in overall survival in patients with HER2 positive metastatic gastric cancer at interim analysis of DESTINY-gastric04 phase 3 trial

March 26, 2025

Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca’s ENHERTU in second-line metastatic gastric cancer DESTINY-Gastric04 will be unblinded at interim analysis based on the superior efficacy of ENHERTU Results will be shared with global regulatory authorities TOKYO &

Business, Health Care, Lifestyle, Money & Financial

Amneal reports fourth quarter and full year 2024 financial results

March 10, 2025

‒ Full year 2024 performance met or exceeded all financial guidance metrics – ‒ Q4 2024 net revenue of $731 million; GAAP net loss of $31 million; diluted loss per share of $0.10 ‒ ‒ Q4 2024 adjusted net income(1) of $40

Business, Health Care, Science

WELIREG® (belzutifan) receives first European Commission approval for two indications

February 22, 2025

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union RAHWAY, N.J. — (BUSINESS WIRE) — $MRK #MRK — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, on Tuesday

Health Care, Local News, Science

New five-year Sotyktu (deucravacitinib) data shows consistent safety and durable response rates in moderate-to-severe plaque psoriasis

February 17, 2025

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and

Health Care, Lifestyle, Local News, Science

UroGen announces results from subgroup analyses of the pivotal ENVISION trial evaluating impact of baseline tumor burden and focality on response to UGN-102

February 16, 2025

Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) CR rates were: 82.8% for patients

Health Care, Lifestyle, Science, Technology

Pulsetto’s global impact: The fastest-growing mental wellness device of 2024 reduces stress and optimizes emotional well-being

February 14, 2025

Surpassing $10M in revenue, Pulsetto processed nearly 40,000 orders in 2024. The company helped over 100,000 users manage stress and emotional well-being, and gained worldwide recognition as a frontrunner in longevity and health optimization. — Nearly half of the global

Business, Health Care, Lifestyle, Science

Zoetis announces US label update for Librela® (bedinvetmab injection), a treatment to control canine osteoarthritis (OA) pain

February 04, 2025

Zoetis plans to immediately implement updated label based on U.S. post-approval experience with Librela Company remains confident in the safety and effectiveness of Librela and reaffirms its commitment to supporting veterinarians and pet owners in helping dogs with OA live with less